Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics to Participate in Upcoming November Investor Conferences

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Faeth Therapeutics announced that its management team will attend two investor conferences in November 2026. The company will hold one-on-one meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 11. Additionally, Faeth will present at the Jefferies Global Healthcare Conference in London on November 17.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth Therapeutics is actively engaging with investors.
  • Participation in notable healthcare conferences.
  • Opportunity to present their lead program, PIKTOR.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
28.8%
average across 2 past catalysts
Cash runway
~40 mo
Low dilution risk
Lead asset
Sapanisertib
Phase 2 · Endometrial Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Wednesday, November 11, 2026 1x1 investor meetings Boston, MA Jefferies Global Healthcare Conference in London Tuesday, November 17, 2026 Presentation at 8:30

Frequently Asked Questions

What conferences will Faeth Therapeutics attend?

Faeth Therapeutics will attend the Guggenheim and Jefferies conferences.

When is the Guggenheim conference?

The Guggenheim conference is on November 11, 2026.

Where is the Jefferies conference held?

The Jefferies conference will be held in London.

What is Faeth's lead program?

Faeth's lead program is called PIKTOR.

ShareAdd on Google
Tags: FTH Faeth Therapeutics PIKTOR investor conferences healthcare innovation
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$175M liquidity · $4M/mo burn
~40 mo
Low dilution risk
Lead asset
SapanisertibPhase 2
Endometrial Cancer →

Catalyst track record

+52%
best trade around FTH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for FTH.

See every catalyst's timing & PoA →